Both show up in the same pre workout tubs and the same nootropic stacks, so it is fair to ask which one actually has evidence behind it for your brain. The honest answer is that neither has the evidence the marketing implies, but they fail in very different ways, and one of them carries a safety question that almost nobody selling it mentions.
If you want the short version: creatine has more and larger human trials, a few of which found modest effects on memory or working memory, mostly in older adults or in people who have been kept awake all night, alongside a large 2023 replication that found almost nothing and a 2024 regulatory review that rejected the cognitive claim outright. Alpha GPC has a handful of tiny acute studies in athletes showing faster reaction times on specific tests, essentially no long term trials in healthy adults, and an observational stroke signal that deserves more attention than it gets.
Two Different Bets On How A Brain Runs Out Of Steam
Creatine and alpha GPC are not competing versions of the same idea. They are two separate hypotheses about what limits your thinking when you are tired or under load.
Creatine is a compound your liver and kidneys make and your muscles and brain store, mostly as phosphocreatine, which is a rapid buffer that regenerates ATP, the molecule cells spend for energy. The theory is that a brain with fuller phosphocreatine stores can sustain demanding mental work a little longer before performance drops. Supplementing does raise brain creatine, though not by much. The BMC Medicine replication trial summarizes the imaging literature this way: an older study found brain creatine rose by about 8.7 percent after 20 g per day for four weeks, and other work has found smaller or inconsistent changes, partly because the brain makes its own creatine and seems more resistant to dietary supply than muscle is.
Alpha GPC, or L-alpha-glycerylphosphorylcholine, is a choline compound. Choline is an essential nutrient and a building block for acetylcholine, a neurotransmitter involved in attention, memory formation and the signal from nerve to muscle. The bet here is that more available choline means more acetylcholine when you need it. It is the same story used to sell citicoline, CDP-Choline and plain choline salts, and it has rarely been tested in healthy people for longer than a single afternoon.
What The Creatine Trials Actually Found
The creatine cognition literature is small but real. Three meta analyses pool it, and each one has a caveat worth knowing.
A 2023 meta analysis in Nutrition Reviews by Prokopidis and colleagues pooled eight randomized trials with 225 healthy participants and reported a small overall improvement in memory measures with creatine versus placebo, a standardized mean difference of 0.29. The interesting part is the subgroup split. In adults aged 66 to 76 the effect was large, 0.88, while in participants aged 11 to 31 it was essentially zero, 0.03. Six of the included trials were rated high risk of bias because they did not describe how randomization was done, and the older adult subgroup rested on only two small studies, one of which found no effect at all. The paper also drew a letter to the editor arguing that double counting of outcomes had produced false positive findings, which the authors replied to. So the headline is real, and so are the weaknesses.
A 2024 meta analysis in Frontiers in Nutrition by Xu and colleagues was broader, pooling 16 randomized trials and 492 participants aged roughly 21 to 76, including both healthy people and patients. It reported significant positive effects on memory, standardized mean difference 0.31, and on attention time, with no clear effect on executive function. Every included trial used creatine monohydrate. That paper has since been criticized on a specific statistical point, which I will come to in the regulatory section.
The 2018 systematic review by Avgerinos and colleagues, cited throughout the later work, reached a cautious version of the same conclusion: possible benefits for short term memory and reasoning, clearer in people under stress and in vegetarians, with a plea for bigger trials.
The plea was answered, and not in the way the field hoped.
The Replication That Should Have Settled It
The most cited creatine and brain study is a 2003 crossover trial by Rae and colleagues in 45 young vegetarian adults, which gave 5 g per day for six weeks and reported large improvements in working memory on the backward digit span and in abstract reasoning on Raven’s matrices. It is the study behind most of the enthusiasm you will read online.
In 2023 a German group led by Sandkühler ran the largest creatine cognition trial to date as a preregistered replication: same dose, same duration, same two primary tests, 123 participants, half vegetarian and half omnivore, double blind and placebo controlled. The working memory effect bordered on significance, p equals 0.064, with an effect size of about 0.17, and the reasoning effect was small and not significant, about 0.09. Eight exploratory tests showed nothing. Vegetarians did not benefit more than omnivores, which contradicts one of the most repeated claims about who creatine helps. And a detail the supplement industry never quotes: side effects were reported significantly more often on creatine than on placebo, with a relative risk of 4.25, mostly mild digestive complaints.
The authors’ own framing is careful and fair. Bayesian analysis gave weak to moderate support for a small effect, and strong evidence against an effect as large as the one Rae reported. In raw terms the working memory improvement was a 0.2 digit longer span, which they translate to roughly 2.5 IQ points if the test were an IQ test, and the reasoning improvement to roughly one point. That is not nothing. It is also not what a 2003 abstract with p below 0.001 led people to expect, and anyone who tells you creatine boosts intelligence without mentioning this study is not reading the literature closely.
The Sleep Deprivation Result, And Why It Is Not About Your Daily Scoop
The most striking recent creatine finding is a 2024 study in Scientific Reports from the Jülich research center in Germany. Fifteen healthy adults took a single oral dose of creatine monohydrate at 0.35 g per kilogram of body weight, or placebo, in the evening and then stayed awake through 21 hours of sleep deprivation while doing cognitive tests and brain scans. Phosphorus and proton magnetic resonance spectroscopy showed changes in brain high energy phosphates, and cognitive performance held up better on creatine, with effects appearing around three hours in and lasting most of the night.
The dose matters enormously here. At 0.35 g per kilogram, a 70 kg person would take roughly 24 g in one sitting, about five times a typical daily serving. The same group followed up in 2026 with a lower single dose of 0.2 g per kilogram in 29 healthy subjects over the same 21 hour protocol, and again reported less deterioration in logical and numerical tasks, language processing speed and psychomotor vigilance, with the authors noting the effect was less pronounced than at the higher dose and that women appeared to benefit more on several tasks. That is still around 14 g for a 70 kg adult, taken once, during a night of no sleep.
Nobody has shown that 5 g a day produces the sleep deprivation result. The mechanism the authors propose, that high circulating creatine plus high brain energy demand temporarily opens up uptake into the brain, is specific to that acute scenario. I find these two studies the most interesting thing in the creatine literature right now, and I also think they are being quietly misread as support for a maintenance dose. They are not that.
What The Alpha GPC Trials Actually Found
Now the other side, and the first thing to say is how thin it is. The clinical history of alpha GPC is as a prescription product in some countries, studied in people with diagnosed cognitive impairment, and a 2024 randomized trial in mild cognitive impairment describes it plainly as a compound used in specific neurological conditions. Those patient studies tell you nothing about a healthy 32 year old trying to focus, and this site does not treat supplements as treatments for any condition, so I am setting that literature aside and looking only at what exists in healthy adults.
What exists is mostly acute, mostly tiny, and mostly funded by ingredient suppliers.
A 2015 crossover study by Parker and colleagues, supported by an alpha GPC manufacturer, gave 20 young adults 200 mg or 400 mg of alpha GPC, 200 mg of caffeine, or placebo, then tested mood, reaction time and a serial subtraction task 30 minutes later. Serial subtraction was 10.5 percent faster on the low dose than placebo. But the authors’ own conclusion states that neither alpha GPC nor caffeine had a statistically significant beneficial effect on mood, cognition or physical performance, in part because of large individual variability. That is a null result with a suggestive number inside it, and it is routinely cited as a positive.
The best designed study in healthy people is a 2024 crossover trial by Kerksick in Nutrients, in which 20 resistance trained men averaging 31 years took placebo, 315 mg or 630 mg of a branded alpha GPC and completed the Stroop, N Back and Flanker tests 60 minutes later and again after a bout of squats. Both doses improved total Stroop score compared with placebo. The Stroop is a test of processing speed and the ability to suppress an automatic response, so this is a reasonable finding about acute attention in a specific group. It is one visit per condition, 20 men, one ingredient supplier’s product, and no measurement of anything lasting past a few hours. The same paper reports no improvement in jump or bench press throw performance.
The physical performance studies are worth a sentence because they are what most alpha GPC content actually rests on. A 2008 pilot by Ziegenfuss, published as a conference abstract, reported a 14 percent increase in peak bench press force in seven resistance trained men after 600 mg. A 2015 trial by Bellar and colleagues gave 13 college aged men 600 mg per day for six days and found greater peak force on an isometric mid thigh pull than placebo, with no effect on the upper body test. Seven men. Thirteen men. These are the foundations of a category. A 2018 study at 500 mg, described in the background of a current trial registration, found no difference in reaction time or visual and verbal memory on a standard concussion style test battery.
There is no published randomized trial of daily alpha GPC over weeks in healthy adults with cognition as the primary outcome that I could find in this research. One is registered: an 80 person, six week trial at 350 mg per day in physically active adults aged 25 to 55, measuring Stroop, sustained attention and digit symbol substitution, both acutely and after six weeks. Until that reads out, alpha GPC benefits for healthy brains are a hypothesis supported by afternoon experiments.
The Alpha GPC Safety Signal That Belongs On The Label
This is the section I most want people to read, because the pages that rank for this comparison are almost entirely product listings and none of them mention it.
Choline compounds can be converted by gut bacteria into trimethylamine, which the liver turns into trimethylamine N oxide, usually called TMAO, a metabolite that has been repeatedly associated with cardiovascular disease. In 2021 a South Korean team used the national health insurance database to ask whether alpha GPC users had more strokes. The cohort study, published in JAMA Network Open, covered more than 12 million adults aged 50 and older without prior stroke, compared people prescribed alpha GPC during 2006 to 2008 with matched non users, and followed them for 10 years. Users had a 46 percent higher risk of stroke, and the risk rose with longer use, from under two months up to more than twelve.
That is an observational finding, and the authors say so. In Korea alpha GPC is a prescription product, so the people taking it were people whose doctors were already worried about their brains, and residual confounding is a real possibility. But the dose response pattern is hard to wave away, and the biology got some support the same year from a mouse study in the International Journal of Molecular Sciences, which found that alpha GPC supplementation raised TMAO, shifted the gut microbiome and markedly increased atherosclerotic lesion area in genetically susceptible mice, with the authors concluding that caution is warranted when using it as a supplement.
The picture is not one sided. A 2025 cohort study from the same Korean database, this time in patients diagnosed with mild cognitive impairment between 2013 and 2016, reported that alpha GPC use did not increase the risk of ischemic or hemorrhagic stroke in that population. Two observational studies from the same country reaching different answers is exactly the situation in which you should not be confident either way. What I can say is that a stroke signal in 12 million people is a bigger fact than a Stroop improvement in 20 men, and it should be weighed accordingly. If you have cardiovascular risk factors or a family history of stroke, this is a conversation for your doctor, not for a supplement label.
Creatine’s safety record is better characterized, mostly because sports scientists have studied it for three decades. The sleep deprivation trial reported no side effects even at the very high single dose. The one honest counterweight is the replication trial’s finding that mild side effects were four times more common on 5 g daily than on placebo. Anyone with kidney disease or on medication that affects the kidneys should talk to a doctor before taking either compound.
What Regulators Concluded When They Read The Same Papers
Two regulatory reviews are relevant, with a caveat about what they mean for products sold in the United States.
In November 2024 the European Food Safety Authority evaluated a health claim application from a major creatine manufacturer proposing that creatine improves cognitive function. The panel concluded that a cause and effect relationship had not been established. Its reasoning is more useful than the verdict. The acute working memory effects it accepted as observed came only from two studies at 20 g per day for five to seven days, and were absent at 2.2 to 14 g per day and absent with 5 g per day for six weeks. A response inhibition effect at 20 g per day was an isolated finding among ten trials in healthy people. And the panel specifically criticized the Xu 2024 meta analysis for pooling multiple related tests from the same participants as if they were independent, which double counts people and inflates the apparent sample size, and said it could draw no conclusions from it. The European Commission is now expected to formally refuse the claim.
In 2011 the same authority reviewed the general choline claims. It accepted three, on lipid metabolism, liver function and homocysteine metabolism, and did not accept the claims for cognitive function or normal neurological function, judging the evidence insufficient at that time. That opinion is still the reference point in Europe for what choline, and by extension the choline delivered by alpha GPC, can be said to do.
Neither ruling binds a US product. In the United States, supplements are regulated under DSHEA, the FDA does not pre approve supplement claims, and structure and function claims such as “supports cognitive function” are legal as long as they carry the standard disclaimer and the seller holds substantiation. The FTC can and does act on unsubstantiated claims. So an American label can say things a European label cannot, which is precisely why it is worth knowing what happened when a regulator sat down with the actual studies.
Who Each Compound Might Plausibly Help
Here is where the creatine evidence points, and where it does not.
Older adults are the most consistent signal, on the strength of the 2023 meta analysis subgroup, with the caveat that it rests on two small trials. People undergoing acute sleep loss are the other, on the strength of the two Jülich single dose studies, with the caveat that the doses were far above anything people normally take. Young healthy adults on a normal night’s sleep are the group with the most data and the least effect, which the replication trial makes uncomfortably clear. Vegetarians, long assumed to be the ideal responders because they eat almost no dietary creatine, did not respond more than omnivores in the one trial large enough to test the question properly.
For alpha GPC the honest answer is that nobody knows who it helps, because the only positive cognitive study in healthy adults is 20 trained men doing a Stroop test an hour after a dose. If you are a strength athlete looking for a marginal acute edge in attention before training, that is the one population with any data. For students, knowledge workers or older adults hoping for something lasting, there is no trial to point to.
What The Studies Used Versus What People Actually Buy
Creatine studies that found anything used either 5 g per day for six weeks, 20 g per day for a week, or single doses of 14 to 24 g in the sleep deprivation work. Most products deliver 3 to 5 g per serving. The EFSA panel’s summary is worth repeating: the effects it accepted appeared at 20 g per day, not at lower doses and not at 5 g daily for six weeks. A 3 g gummy is not a 20 g loading phase.
Alpha GPC studies used 200 to 630 mg as a single dose, or 600 mg per day for six days. Combination products on the US market commonly pair 5 g of creatine monohydrate with 600 mg of alpha GPC in one scoop. Those numbers are individually drawn from studies, which lets a label describe them as clinically studied amounts. What has never been studied is the combination, and that phrase is doing a lot of work.
Creatine monohydrate is also among the cheapest supplements sold, which changes the calculation. A small, uncertain benefit at a few dollars a month is a different proposition from a small, uncertain benefit plus an unresolved cardiovascular question at a considerably higher price.
Taking Both, And What The Evidence Does Not Say
People will ask whether to stack them, since the mechanisms differ. I cannot find a single trial testing creatine and alpha GPC together on any cognitive outcome. Additive effects are a guess. The one thing you can say with confidence is that stacking does not reduce the alpha GPC safety uncertainty, and it does not turn creatine’s borderline working memory effect into something you would notice on a Tuesday.
If you are going to try one on the basis of the current evidence, the choice is not close. Creatine monohydrate has larger trials, a possible small effect in older adults, a replicated acute effect under sleep deprivation at doses you should think carefully about, a decades long safety record and a low cost. Alpha GPC has a plausible mechanism, a few afternoon experiments in athletes, and a 12 million person stroke signal that has not been resolved. That ranking is about the state of the research in September 2026. It is not a promise about what either will do for you.
What Would Change This Picture
For creatine, the study that would move me is a large, preregistered trial in adults over 60 using 5 g per day for several months with memory as the primary outcome. The older adult signal is real enough to deserve that, and it currently rests on fewer than 60 people. A trial of 10 to 20 g per day in sleep restricted shift workers, rather than a single lab night, would tell us whether the Jülich result has any everyday relevance.
For alpha GPC, the registered six week trial at 350 mg is the first thing to watch. If 80 healthy adults show nothing after six weeks, the healthy adult case is close to finished. If they show something, it would still need replication at a dose people actually use. And on safety, the field needs a prospective study, ideally with TMAO measured, in people taking alpha GPC as a supplement rather than as a prescription for cognitive complaints. Until that exists, the stroke question stays open, and open is not the same as answered in the supplement’s favor.